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Abstract
Background: Laeverin is a placenta-specific membrane-bound aminopeptidase. In this study we wanted to: 1)
serially measure plasma levels of laeverin in healthy women during the second half of pregnancy and postpartum,
2) determine whether laeverin is differently expressed at 22–24 weeks in women who later develop preeclampsia
compared to controls, 3) compare laeverin protein expression in placenta and umbilical vein serum in healthy and
preeclamptic pregnancies at birth.
Methods: Plasma was obtained serially, approximately every 4-weeks, from 53 healthy women with uncomplicated
pregnancies during 22+0 to 39+6 weeks of gestation, and at 22–24 weeks from 15 women who later developed
preeclampsia. Enzyme-linked immunosorbent assay was used to measure laeverin protein concentration. Serum
from healthy non-pregnant premenopausal women (n = 10), menopausal women (n = 10) and men (n = 11) were
used as negative controls. Protein extracts from placental tissue were obtained after birth from healthy- (n = 11) and
preeclamptic women (n = 13). Paired umbilical artery and vein serum samples from the neonates (n = 10) of healthy
mothers were also analyzed. Multilevel modeling was used to determine the reference centiles. Differences
between groups were analyzed using Student’s t-test.
Results: Healthy pregnant women at term (37–40 weeks) had significantly higher plasma levels of laeverin (mean 4.
95 ± 0.32 ng/mL; p < 0.0001) compared to men (mean 0.18 ± 0.31 ng/mL), non-pregnant premenopausal women
(mean 0.77 ± 0.26 ng/mL) and postmenopausal women (mean 0.57 ± 0.40 ng/mL). Maternal plasma laeverin levels
decreased with advancing gestation, from 6.96 ± 0.32 ng/mL at 22–24 weeks to 4.95 ± 0.32 ng/mL at term (p < 0.
0001) in uncomplicated pregnancies. Half of the women who developed preeclampsia had plasma laeverin levels
below the 5th percentile at 22–24 weeks gestation. However, laeverin levels were 1.6 fold higher in preeclamptic
compared to healthy placentas (p = 0.0071). Umbilical venous samples of healthy neonates (n = 38) had higher
(p = 0.001) mean levels of laeverin (16.63 ± 0.73 ng/mL), compared to neonates of preeclamptic (n = 14) mothers
(12.02 ± 1.00 ng/mL). Postpartum plasma levels of laeverin decreased in healthy and preeclamptic women with
a half-life of 3 and 5 days, respectively.
Conclusions: Maternal plasma levels of laeverin decrease with advancing gestation during the second half of
normal pregnancy and lower levels measured at 22–24 weeks might be associated with the development of
preeclampsia later in gestation.
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Background
Laeverin (aminopeptidase Q) is a protein that is expressed
by human villous trophoblasts [1]. More specifically, we
showed previously that laeverin is expressed in the plasma
membrane of villous trophoblasts in normal placentas,
but in preeclamptic placentas it is ectopically expressed in
the cytoplasm and secreted within microvesicles in the
fetal capillaries [2]. These observations indicate that lae-
verin might be an attractive biomarker of preeclampsia.
However, laeverin levels in maternal and fetal plasma dur-
ing normal pregnancy and/or preeclampsia have not been
investigated.
We hypothesized that plasma laeverin levels vary with
gestational age during the second half of pregnancy and
laeverin is differentially expressed in normal and pre-
eclamptic pregnancies.
In this study we aimed to 1) serially measure plasma
levels of laeverin in healthy women during the second
half of pregnancy and postpartum to establish longitu-
dinal reference ranges, 2) determine whether laeverin
plasma levels measured at 22–24 weeks are different in
women who later develop preeclampsia compared to con-
trols, and 3) compare laeverin protein expression in pla-
centa and umbilical vein serum in healthy and preeclamptic
pregnancies at birth.
Methods
The study was approved by the Regional Committee for
Medical and Health Research Ethics-North Norway
(REK Nord ref. number 5.2005.1386 (approved 27.09.05)
and 2010/2058–4 (approved 13.01.05)) and informed
written consent was obtained from all the participants.
Study population
Fifty-three healthy pregnant women were recruited to
the longitudinal arm of the study [3]. Blood samples were
obtained serially between 22 and 40 weeks of gestation at
approximately 4-weekly intervals (a total of 243 samples).
Furthermore, blood samples were obtained from 42 of
these healthy mothers at 1–6 days postpartum. Umbilical
cord blood samples were obtained from 38 neonates
immediately after birth.
Among a total of 641 pregnant women recruited to the
cross-sectional arm of the study [3], 29 (4.5%) developed
preeclampsia. Preeclampsia was defined as blood pressure
(BP) of at least 140 mmHg (systolic) and/or 90 mmHg
(diastolic) with proteinuria ≥1+ on dipstick, measured on
at least two occasions 6 h apart after the 20th week of
gestation. Women with pre-existing chronic hypertension,
renal disease, lupus erythematosus, diabetes, and gestational
hypertension without proteinuria were excluded. We had
plasma samples from 15 of these women obtained at 22–24
weeks of gestation that were analyzed for laeverin. Postpar-
tum (2–6 days) samples were also available from 4 of these
women. Umbilical cord samples from 14 neonates from
preeclamptic mothers were obtained immediately after
birth.
Serum samples from eleven healthy men, ten healthy
non-pregnant premenopausal women, and ten menopausal
women were used as negative controls. All participants of
the study were white Europeans.
Paired umbilical arterial and venous serum samples
from the neonates of 10 healthy women with uncompli-
cated pregnancies were used to evaluate the arterial-
venous gradient of laeverin concentration.
Collection of serum and plasma samples
Peripheral blood samples were collected in EDTA or serum
tubes, incubated at room temperature for 30 min and centri-
fuged at 1200×g for 10 min. Upper serum or plasma phase
was collected and immediately frozen at −70 °C before
further analysis.
Placental tissue protein samples
Placental samples from 11 healthy and 13 preeclamptic
women were used for protein isolation and laeverin quanti-
fication. Placental tissue samples were obtained immedi-
ately after delivery as described previously, snap frozen and
stored for further use [4]. Placental tissue was cut in pieces
and homogenized using MagNA Lyser Green Beads on
MagNA Lyser (Roche, USA). Proteins were isolated using
T-PER (Pierce, USA) with Complete Mini EDTA-free
protease inhibitor cocktail (Roche, USA). Total protein
concentration was measured using DC Protein Assay
kit (BioRad, USA) in a ThermoMax Microplate Reader
(Molecular Devices, USA). Total protein from 11 healthy
placentas and 13 preeclamptic placentas was isolated.
Human Aminopeptidase Q levels (AP-Q ELISA Kit)
Serum, plasma and protein samples were adjusted to
room temperature. Enzyme-linked immunosorbent assay
(ELISA) analysis was performed according to the manu-
facturer’s specifications (EIAab Science co., Ltd, Wuhan,
China). ELISA is a specific and sensitive method for detec-
tion of small amounts of protein in serum [5, 6]. Measure-
ments were performed in duplicate by a single investigator
(MN). Optical density was measured using a ThermoMax
Microplate Reader (Molecular Devices, USA) at 450 nm.
Concentrations were estimated relating it to a standard
curve of laeverin protein provided by the manufacturer. A
calibration curve was plotted using absorbance (y-axis)
against the concentration (x-axis). The mean absorbance
was calculated for each set of standards, controls and
samples and then subtracted the mean zero STD from
each. Unknown concentration was determined by the
interpolation method.
For quantification studies of the total placental protein
samples from healthy and preeclamptic women 50 μg
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total protein was added to each well. Laeverin concen-
tration was then derived from standard curves.
Total protein, extracted from placental samples, was
used as positive controls of laeverin expression for valid-
ation of the kit. The lowest standard concentration of
the assay was 2 ng/mL and the minimum detectable
amount of the kit was 0.312 ng/mL (according to the manu-
facturer). The kit has sensitivity to detect concentrations
down to 0.156 ng/mL. Intra- and inter-assay coefficients of
variation (CV) calculated from duplicate patient samples in
the concentration range 0.312–20 ng/mL were <6%.
Statistics
Analysis of the longitudinal data was performed using
SAS v.9.4 (SAS Institute Inc. Cary, NC). Multilevel mod-
eling was used to estimate the reference percentiles [7].
SPSS software (IMB SPSS Statistics 22, Armonk, NY,
USA) was used for the analysis of cross-sectional data.
Sensitivity, specificity, positive predictive value and negative
predictive value were calculated to evaluate usefulness of
laeverin in predicting preeclampsia setting a cut-off value
at ≤5 ng/mL. Differences between groups were evaluated
using Student’s t-test for parametric variables and
Mann-Whitney U test for non-parametric variables. Linear
mixed model ANOVA was used to evaluate the differences
in laeverin concentrations between different gestational
weeks antenatally and different days post-partum. A
P-value <0.05 was considered statistically significant.
Results
Phenotype of the study population
The phenotype of the study population is presented in
Table 1. The demographic and clinical characteristics of
women included in the longitudinal arm of the study
have been reported previously.[3] Briefly, all the 53 par-
ticipants were healthy women, and none of them devel-
oped any significant pregnancy complications. Follow up
data on the course of pregnancy and perinatal outcome
were available for all the participants.
Three (5.6%) women had cesarean section; two due to
dystocia and one because of breech presentation. Six
(11.2%) women had vacuum delivery; four due to failure
to progress and two because of fetal distress in the sec-
ond stage of labor.
Pregnant women participating in the cross-sectional
arm of the study who developed preeclampsia (n = 15)
had higher BMI, higher mean uterine artery pulsatility
index, and were delivered at an earlier gestation (32 weeks
(n = 1), 36 weeks (n = 1), 39 weeks (n = 3), 40 weeks (n =
3) 41 (n = 6) weeks and 42 (n = 1) weeks). Two (13%)
women had cesarean section, three (20%) women were de-
livered by vacuum extraction and ten (67%) had normal
vaginal delivery.
The baseline clinical characteristics and pregnancy
outcome of the healthy (n = 11) and preeclamptic women
(n = 13) whose placentas were used for placental laeverin
quantification are presented in Table 2.
Table 1 Phenotype of the study population (healthy pregnant women participating in the longitudinal arm of the study and
women participating in the cross-sectional arm of the study who developed preeclampsia). Continuous variables are presented as
mean ± SE or median (range) and categorical variables as n (%) as appropriate. Doppler ultrasonography was performed at 22–24
weeks of gestation
Longitudinal study Women who developed preeclampsia P
valueHealthy women (n = 53) Preeclampsia (n = 15)
Maternal age, median (range), years 28.7 (18–39) 27.5 (18–40) 0.368
Body mass index before delivery, (kg/m2) 25.11 ± 0.41 25.75 ± 1.08 0.504
Primipara, n (%) 36 (68) 8 (53.3) 0.304
Mean arterial pressure, mmHg 79.40 ± 3.12 87.55 ± 1.28 0.003
Uterine artery pulsatility index (mean of the left and right side) 0.80 ± 0.02 1.24 ± 0.04 0.000
Middle cerebral artery pulsatility index 1.62 ± 0.06 1.82 ± 0.05 0.070
Umbilical artery pulsatility index 0.80 ± 0.02 1.24 ± 0.04 0.000
Gestational age at delivery, median (range), weeks 40 (37–42) 39 (32–41) 0.849
Cesarean section, n (%) 3 (5.66) 2 (13.33) 0.322
Neonatal birth weight, g 3562 ± 65 3329 ± 163 0.122
Placental weight, g 591 ± 17 584 ± 22 0.833
5 min APGAR score median (range) 10 (7–10) 9 (6–10) 0.472
Arterial cord blood pH 7.24 ± 0.02 7.23 ± 0.03 0.829
Arterial cord blood Base Excess, mmol/L −5.65 ± 0.62 −3.59 ± 1.45 0.164
Venous cord blood pH 7.36 ± 0.01 7.35 ± 0.02 0.816
Venous cord blood Base Excess, mmol/L −4.50 ± 0.45 −4.11 ± 1.35 0.731
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The neonates (n = 10) of healthy mothers whose um-
bilical cord blood samples were used to determine
arterio-venous gradient of laeverin concentration were
all delivered at term and had a mean birth weight of
3317 ± 200 g, placental weight 566 ± 38 g and normal
umbilical artery pH (7.26 ± 0.04) and base excess
(−1.05 ± 1.25 mmol/l).
Serum laeverin levels in healthy men and non-pregnant
controls
Healthy men (mean 0.18 ± 0.31 ng/mL), non-pregnant
premenopausal women (mean 0.77 ± 0.26 ng/mL) and
postmenopausal women (mean 0.57 ± 0.40 ng/mL) had
very low levels of laeverin (mean 0.50 ± 0.19 ng/mL).
Plasma laeverin levels in healthy women during the
second half of pregnancy
Gestational age specific longitudinal references ranges
for maternal plasma laeverin concentration during the
second half of pregnancy are presented in Table 3 and
Fig. 1. Laeverin levels decreased with advancing gesta-
tion, from 6.96 ± 0.32 ng/mL at 22–24 weeks to 4.95 ±
0.32 ng/mL at term (37–40 week) (p < 0.0001). We
found significantly lower laeverin levels on postpartum
day 2 (p = 0.0454) and 3 (p = 0.01) compared to the
antepartum laeverin levels, but the difference was not
statistically significant on the first postpartum day.
Laeverin levels decreased further after delivery from a
median value of 4.98 ng/mL on 1st day postpartum to
1.31 ng/mL on 6th day postpartum (Fig. 2). We
performed mixed model ANOVA and found a signifi-
cant difference (p = 0.0055) in laeverin levels between
different postpartum days. In the postpartum period,
in healthy women, laeverin protein half-life (t1/2) was
3 days.
Table 2 Clinical characteristics and pregnancy outcomes of placentas used for tissue laeverin protein quantification. Continuous
variables are presented as mean ± SE or median (range) and categorical variables as n (%) as appropriate. Doppler ultrasonography
was performed < 24 h before delivery
Healthy women (n = 11) Preeclampsia (n = 13) P value
Maternal age, median (range), years 27 (19–32) 29 (21–36) 0.562
Body mass index before delivery, (kg/m2) 23.49 ± 1.56 27.20 ± 1.66 0.118
Primipara, n (%) 7 (63.6) 6 (46.2) 0.532
Mean arterial pressure, mmHg 92.17 ± 1.91 130.85 ± 2.92 0.000
Uterine artery pulsatility index (mean of the left and right side) 0.66 ± 0.04 1.76 ± 0.34 0.028
Middle cerebral artery pulsatility index 1.06 ± 0.10 1.46 ± 0.12 0.006
Umbilical artery pulsatility index 0.73 ± 0.05 1.05 ± 0.08 0.028
Gestational age at delivery, median (range), weeks 40 (34–42) 35 (29–39) 0.024
Cesarean section, n (%) 1 (9.1) 9 (69) 0.005
Neonatal birth weight, g 3516 ± 201 2690 ± 248 0.018
Placental weight, g 622 ± 65 522 ± 54 0.247
5 min APGAR score median (range) 9 (8–10) 9 (5–10) 0.435
Arterial cord blood pH 7.28 ± 0.02 7.24 ± 0.03 0.457
Arterial cord blood Base Excess, mmol/L −3.46 ± 1.52 −2.20 ± 1.52 0.582
Venous cord blood pH 7.35 ± 0.01 7.29 ± 0.02 0.043
Venous cord blood Base Excess, mmol/L −4.16 ± 1.07 −1.72 ± 1.44 0.270
Table 3 Longitudinal reference ranges for maternal plasma
laeverin concentration during the second half of pregnancy
Gestation (weeks) Percentiles
2.5th 5th 10th 50th 90th 95th 97.5th
22 3.6 4.0 4.5 6.9 10.3 11.5 12.6
23 3.5 3.9 4.4 6.7 10.1 11.3 12.4
25 3.3 3.7 4.2 6.4 9.7 10.9 12.0
26 3.2 3.6 4.1 6.3 9.5 10.7 11.8
27 3.1 3.5 3.9 6.1 9.4 10.5 11.6
28 3.0 3.4 3.8 6.0 9.2 10.4 11.5
29 2.9 3.3 3.7 5.9 9.1 10.2 11.3
30 2.8 3.1 3.6 5.7 8.9 10.1 11.2
31 2.7 3.0 3.5 5.6 8.8 9.9 11.0
32 2.6 2.9 3.4 5.5 8.6 9.8 10.9
33 2.5 2.8 3.3 5.3 8.5 9.7 10.8
34 2.4 2.7 3.2 5.2 8.4 9.6 10.7
35 2.3 2.6 3.1 5.1 8.3 9.4 10.6
36 2.2 2.5 3.0 5.0 8.2 9.3 10.5
37 2.1 2.5 2.9 4.9 8.0 9.2 10.4
38 2.1 2.4 2.8 4.8 7.9 9.1 10.3
39 2.0 2.3 2.7 4.6 7.8 9.0 10.2
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Plasma laeverin in women developing preeclampsia
Plasma laeverin concentrations of 15 women at 22–24
weeks of gestation, who later developed preeclampsia, plot-
ted against the normal longitudinal reference curves, are
shown in Fig. 1 (median concentration of 3.99 +/−2.51
(SD) and p = 0.006). In four women (27%), plasma laeverin
levels were between 50-75th percentile, three women
(20%) had laeverin levels below the 50th percentile and
eight (53%) had below the 5th percentile. In women devel-
oping preeclampsia, the plasma laeverin concentration
decreased postpartum from 4.27 ng/mL on 2nd day to un-
detectable level on the 6th day after delivery. The half-life
of postpartum laeverin was 5 days in preeclamptic
women. Among the 15 preeclamptic women, only one
had severe (i.e., BP ≥ 160/110 with +2 proteinuria)
early-onset (i.e., less than 34 weeks gestation) disease.
The serum laeverin levels of this woman were not sig-
nificantly different compared to the rest of the pre-
eclamptic women (p = 0.069).
With a cut-off value for laeverin concentration set
at ≤5 ng/mL, the sensitivity, specificity, positive predictive
value and negative predictive value for the prediction of
preeclampsia were 0.60, 0.79, 0.82 and 0.88, respectively.
Placental tissue laeverin protein quantitation
Placental tissue of 83 mg gave 5 μg total protein, of
which 0.26 ng was laeverin protein. Laeverin protein con-
centration was 1.6 fold higher in preeclamptic placentas
(mean 8.29 ± 0.73 ng/mL) compared to healthy placentas
(mean 5.18 ± 0.75 ng/mL) (p = 0.0071).
Umbilical cord blood laeverin concentration
The neonates of the healthy mothers had a mean laeverin
concentration of 16.63 ± 0.73 ng/mL in the umbilical vein
serum samples with no significant difference between girls
(n = 22) and boys (n = 16) (16.20 ± 1.05 ng/mL versus
17.22 ± 0.99 ng/mL, respectively; p = 0.111). In the neonates
of women who had preeclampsia (n = 14), the mean lae-
verin level in the umbilical vein was significantly lower
(12.02 ± 1.00 ng/mL) compared to healthy pregnancies
(p = 0.001).
Arterial-venous gradient of laeverin in the umbilical cord
blood
Concentration of laeverin was checked in paired umbilical
artery and vein serum samples of 10 healthy neonates of
mothers who had uncomplicated pregnancies. The differ-
ence between umbilical artery (mean, 14.12 ± 0.91 ng/mL)
and vein (mean, 15.46 ± 1.17 ng/mL) was not statistically
significant.
Discussion
This is the first study to investigate gestational age-
associated longitudinal changes in plasma laeverin levels
in healthy women with uncomplicated pregnancies. We
found that plasma laeverin levels gradually decrease with
advancing gestation during the second half of pregnancy
and are undetectable few days after delivery. The reasons
for decreasing levels of laeverin are unclear. As laeverin
is a placenta-specific protein, it is likely to have an im-
portant role in the process of placentation during early
pregnancy, but less might be required after this process
is complete. Indeed, we showed previously that laeverin
effects migration and invasion of first trimester trophoblast
Fig. 1 Maternal plasma laeverin concentration (ng/ml) in healthy
pregnant women during the second half of pregnancy and maternal
plasma laeverin concentration at 22–24 weeks in women who later
developed preeclampsia. The solid line represents the 50th percentile
and the interrupted lines represent the 5th and 95th percentiles for
the gestational age. Circles represent healthy pregnant women and
red crosses laeverin protein expression at 22–24 weeks in women who
later developed preeclampsia
Fig. 2 Box-and-whisker plots showing plasma laeverin levels (ng/ml)
levels in 41 healthy women at gestational week 37–39 (timepoint 0)
and at 1–4 days post-partum. Grey boxes represent upper quartile,
white boxes represent lower quartile and the line between them
represents the median value of each series. Whiskers represent the
highest and lowest points within the range
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cells [2]. Alternatively, as total plasma volume increases
normally during pregnancy, the reduction of plasma lae-
verin levels might be seen due to dilution effect.
Furthermore, we found lower plasma levels of laeverin
at 22–24 weeks in women who later developed pre-
eclampsia compared to healthy controls. These women
most likely had shallow placentation. We have previously
shown that laeverin is overexpressed in preeclamptic
placenta both at mRNA as well as protein level [2, 4].
This leads us to speculate that laeverin might be trapped
in the placenta during the development of preeclampsia.
In fact, tissue protein quantification showed a 1.6 fold
increase of laeverin protein in preeclamptic compared to
healthy placentas. This is despite of generally reduced
placental size in preeclamptic pregnancies [8]. We have
previously shown an abnormal expression of laeverin in
cytoplasm of trophoblast cells in preeclamptic placentas,
which may indicate deregulation or improper folding of
the protein [2]. It is known that preeclampsia leads to in-
creased apoptosis of cytotrophoblasts or cell death [9, 10],
which might explain why laeverin accumulates in pre-
eclamptic placentas. Furthermore Horie et al. demon-
strated that laeverin is intensely expressed on the surface
of extravillous trophoblasts invading maternal decidua and
vessels [11]. Since defective endovascular invasion of extra-
villous trophoblast has been considered to be a primary
cause of preeclampsia it is possible that reduced number of
extravillous trophoblast colonizing inside the maternal ves-
sels could be one of the causes of lower plasma laeverin at
22–24 weeks of gestation in the women who later devel-
oped preeclampsia.
Preeclampsia is associated with increased apoptosis or
cell death of cytotrophoblasts. The exact molecular mech-
anisms behind these phenomena are not known. It is sug-
gested that endoplasmatic reticulum stress can lead to cell
apoptosis and protein degradation [12, 13]. Therefore, we
hypothesize that the observed accumulation of laeverin in
the cytoplasm of cytotrophoblasts of preeclamptic pla-
centas could be explained by defective protein glycosyl-
ation and/or misfolding occurring in the endoplasmatic
reticulum [13, 14].
Another possible explanation of the reduced laeverin
protein expression in the maternal circulation might be
that laeverin is trapped in microvesicles in the fetal capil-
laries in the placenta of preeclamptic patients [2]. How-
ever, even if these microvesicles were transported to the
maternal circulation, we would not be able to detect lae-
verin inside them, since our present ELISA-method did
not include isolation and disruption of microvesicles.
Moreover, we found similar laeverin concentrations in the
umbilical artery and vein indicating that there is no signifi-
cant production or metabolism of laeverin in the fetus.
This is in line with the previous studies, demonstrating
that placenta is the major organ producing laeverin [1].
Our study has some limitations. Samples were stored
for up to 5 years at −70°C and some samples were
thawed once. However minimal differences in laeverin
levels were found when thawed and non-thawed samples
were compared (data not shown). In a study by Rana et al.
minimal effect on plasma and serum quality was seen
when samples were thawed several times [15]. Further, we
were able to include only a small number of samples
from preeclamptic women. Therefore, this study should
be reproduced in a bigger cohort, and preferably first
trimester samples should also be included.
We used a commercial kit to measure laeverin concen-
tration, which has not been previously validated for use in
the context of pregnancies and placenta samples. There-
fore, we performed extensive validation prior to analysis.
Healthy men, non-pregnant premenopausal women and
menopausal women had a very low expression of laeverin
indicating that laeverin is a placenta-specific protein and
the aminopeptidase Q ELISA kit appeared to be a versatile
test for the quantitation of laeverin in serum-, plasma-
and placental tissue protein samples.
Conclusions
In conclusion, our longitudinal study showed that the ma-
ternal plasma laeverin concentration gradually decreases
during the second half of normal pregnancy. Women who
later developed preeclampsia had lower levels of laeverin
compared to healthy controls at 22–24 weeks of gestation
in our cohort. Further research is needed to investigate
the potential role of laeverin as a predictive biomarker of
preeclampsia.
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